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Summary
Background There are ongoing concerns about the quality of care
provided to patients with allergic disorders in Scotland, but there are
relatively few reliable data on the overall disease burden.We sought to: (1)
describe the incidence, prevalence and outcome of allergic disorders; (2)
estimate healthcare burden and costs; and (3) investigate ethnic variations in
the epidemiology and outcomes from allergic disorders in Scotland.
Methods Data sources: national surveys; primary care data; prescribing
and medication data; hospital admissions data and mortality data.
Results Allergic disorders are extremely common in Scotland, affecting
about one in three of the population at some time in their lives. Incidence
was highest for eczema (10.2 per 1000 registered patients). Over 4% of all GP
consultations and 1.5% of hospital admissions were for allergic disorders.
There were 100 asthma deaths in 2005 (20 per million people). Direct
healthcare costs for allergic disorders were an estimated £130 million per
year, the majority of these being incurred in primary care and related to
asthma.
Conclusions Allergic disorders are common in Scotland and given the
very high proportion of children now affected, the high disease burden
associated with these conditions is likely to persist for many decades.
Introduction
In recent decades, there has been a dramatic
increase in the prevalence of a number of allergic
disorders in the UK, resulting in considerable
challenges to an ill-prepared National Health
Service (NHS).1–4 Concerns regarding the quality
of allergy care were particularly highlighted in the
Royal College of Physicians report Allergy: the
unmet need,5 which in turn precipitated parliamen-
tary enquiries into allergy care provision in both
England6 and Scotland.7,8
Much of the epidemiological work under-
pinning the Royal College of Physicians reportwas
based on detailed secondary analyses of avail-
able healthcare data-sets, with a focus on those
data-sets most relevant to England and Wales.1
Important data-sets of particular relevance to the
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Scottish contextwere, because of time and resource
constraints, in the main overlooked.9
The aim of this study was to describe the epi-
demiology, morbidity, mortality and economic
costs to NHS Scotland of allergic disorders. In
seeking to answer these questions, we focused on
the following conditions: allergic conjunctivitis;
allergic rhinitis; anaphylaxis; angioedema; asthma;
drug allergy; eczema/atopic dermatitis; food
allergy; urticaria; and allergies not classified
elsewhere. Our secondary aim was to investigate
ethnic variations in the epidemiology and out-
comes from these allergic disorders. In addition,
Scotland’s position in international allergy rank-
ings was considered.
Methods
Data-sets
Data were collected from routine health infor-
mation sources and large, high quality national
and international surveys. Surveys included the
1995, 1998 and 2003 Scottish Health Surveys
(SHS),10 the 2001 Health Survey for England (HSE)
for comparative purposes,11 and the International
Study of Allergies and Asthma in Childhood
(ISAAC).12 Appendix 1 shows questions on allergy
used in these surveys. Primary care healthcare
data were obtained through the Information
Services Division (ISD) of NHS National Services
Scotland, for the Practice Team Information pro-
gramme13 and the Quality and Outcomes Frame-
work14 of the General Medical Services contract,
from the Primary Care Clinical Informatics Unit,
and from the QRESEARCH programme.15 Data on
prescribing were provided by the Prescription
CostAnalysis programme16 (part of ISD) and from
over-the-counter sales17 for prescribing and medi-
cation. Data for continuous inpatient stays (the
same continuous spell of inpatient treatment) were
provided by ISD from the Scottish Morbidity
Record (SMR01)18 and mortality data from the
General Register Office for Scotland (GROS).19 A
description of the salient features of these data-sets
is given in Appendix 2.
Definitions
Allergic disease definitions were based on
those used in the SHS, HSE and ISAAC surveys
(Appendix 1), Read codes for primary care data
(Appendix 3) and theWorldHealthOrganization’s
(WHO) International Classification of Diseases
(ICD 10) codes for SMR01 (Appendix 4).
Statistical methods
Incidence rates from primary care were calculated
as the number of new cases of disease diagnosed in
a specific year divided by the total number of
patients registeredwith the study practices for that
year (to give person years of exposure). These rates
were multiplied by 1000 to give rates per 1000
registered patients per year. Lifetime prevalence
was estimated from the number of GP patients
with a recorded diagnosis of the disease at any
point since being registered with a practice di-
vided by the total number of patients registered
with the study practices. These rates were stand-
ardized by sex and five-year age bands using the
estimated mid-year Scottish population (obtained
from GROS population estimates). Rates were
multiplied by 1000 to give rates per 1000 registered
patients. These rates were also standardized by
sex and five-year age bands using the estimated
mid-year (2004) English population and multi-
plied by 1000 to give rates per 1000 registered
patients to compare with English primary care
(QRESEARCH) data. All analyses were under-
taken using SPSS v 13.0.
Assessing costs
The cost of GP consultations, hospital inpatient
stay and day cases were calculated using unit costs
and national estimates for measures of healthcare
utilization.20,21 Community prescription costs
were estimated using ISD prescription data using
the standard Defined Daily Dose (DDD) andGross
Ingredient Cost (GIC). The DDD, as defined by the
WHO is the assumed average maintenance dose
per day for a drug when used for its main indica-
tion in adults.22 The GIC is the cost of an item
before any discounts that may be made by the
supplier to pharmacies; it does not include dis-
pensing costs or fees. Fees paid by the recipient are
also excluded; this equates with the Net Ingredient
Cost.23
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Results
Incidence, prevalence and outcomes of
allergic disorders
There were 12,210 incident cases of allergy in pri-
mary care in 2003–2004. The overall incidence rate
of a primary care diagnosis of any allergic disorder
was 32 per 1000 registered patients (95% CI 31–33)
in 2003–2004 (Table 1). Incidence was higher in
women (37 per 1000 registered patients) than men
(27 per 1000 registered patients). The highest inci-
dence in 2003–2004was for eczema at 10.2 per 1000
registered patients (95% CI 9.9–10.5) for people of
all ages and for both sexes combined. Incidence of
eczema was higher in women (11.6 per 1000 regis-
tered patients) than men (8.8 per 1000 registered
patients). The lowest incidence in 2003–2004 was
for anaphylaxis at 0.02 per 1000 registered patients
(95% CI 0.01–0.04) for people of all ages and for
both sexes combined and was higher in women
(0.04 per 1000 registered patients) than men (0.02
per 1000 registered patients). The recording of eth-
nicity in primary care was insufficient to permit
analysis.
During the 12 months ending in March 2006,
8.3% of men and 10.5% of women consulted their
practice with any diagnosis of allergic disease
(PCCIU, data not shown). The lifetime prevalence
for all allergies in Scotland (in 2004), based on
general practice consultations, was substantially
higher at 350 (95% CI 348–352) per 1000 registered
patients, compared to 243 (95% CI 243–245) per
1000 registered patients for England (in 2005)
(Appendix 5). Prevalence was higher in Scotland
when compared to England for allergic rhinitis,
asthma and eczema, but not for anaphylaxis (Table
1, Appendix 5).
Asthma posed a particularly high disease bur-
den. The proportion of respondents aged 16 years
or over in the 2003 SHS who reported ever having
wheezed was 27% in men and 26% in women
(Table 2, Appendix 6). Among adult respondents
to the 2003 survey, 13% of men and 14% of women
reported that they had ever had asthma diagnosed
by a doctor.
The lifetime prevalence of doctor-diagnosed
asthma among children under 16 years in 2003was
20% in boys and 12% in girls. The prevalence of
wheeze within the last 12 months was 16% in boys
and 12% in girls. The corresponding figures for
lifetime wheeze were 29% and 20% (Appendix 6).
Although ethnic group is recorded in the SHS the
number of respondents from ethnic minorities was
too small to allow separate analysis.
The 2002 ISAAC survey of 12–14-year-olds in
Scotland (based on self-reports) found an overall
prevalence of wheezing in the past 12 months of
28% and the lifetime prevalence of asthmawas 26%,
similar to the rest of the UK (data not shown).12 The
lifetime prevalence of diagnosed asthma increased
slightly from 20% in 1995 to 24% in 2002.12
Table 1
Incidence of new primary care diagnoses; 95% confidence interval (CI) by gender and diagnosis; rate per
1000 registered patients per year, Scotland 2003–2004 (Source: PCCIU)
Disease Incidence in men Incidence in women Total incidence
(95% CI) (95% CI) (95% CI)
All allergy 27 (26–28) 37 (36–38) 32 (31–33)
Allergic rhinitis 5.4 (5.0–5.7) 6.8 (6.5–5.4) 6.1 (5.9–6.3)
Anaphylaxis 0.02 (0.01–0.03) 0.04 (0.01–0.07) 0.02 (0.01–0.04)
Angio-oedema 0.03 (0.00–0.06) 0.05 (0.02–0.08) 0.04 (0.02–0.06)
All asthma 4.2 (3.9–4.5) 5.4 (5.1–5.7) 4.8 (4.6–5.0)
Allergic asthma 0.04 (0.01–0.07) 0.06 (0.03–0.09) 0.05 (0.03–0.07)
Conjunctivitis 0.84 (0.71–0.97) 1.6 (1.5–1.8) 1.2 (1.1–1.4)
Drug allergy 1.7 (1.5–1.9) 3.2 (2.9–3.5) 2.5 (2.3–2.6)
Eczema 8.8 (8.4–9.2) 11.6 (11.1–12.1) 10.2 (9.9–10.6)
Food allergy 0.17 (0.11–0.23) 0.22 (0.15–0.28) 0.19 (0.15–0.24)
Urticaria 2.7 (2.5–2.9) 4.1 (3.8–4.4) 3.4 (3.2–3.6)
Other allergies 1.7 (1.5–1.9) 3.2 (2.9–3.5) 2.5 (2.3–2.6)
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The 2002 ISAAC survey in Scotland showed an
overall prevalence of a rhinoconjunctivitis in the
previous 12 months of 17%, with a lifetime preva-
lence of hayfever of 36%, slightly lower than the
rest of the UK (data not shown). Between 1995 and
2002 there was a slight decrease in the prevalence
of rhinoconjunctivitis in the previous 12 months
among 12–14-year-olds in Scotland from 19% to
17%.12
The 2002 ISAAC survey in Scotland showed
an overall prevalence of a flexural rash in the past
12 months of 13% while the lifetime prevalence of
eczemawas 24%, similar to the rest of the UK (data
not shown). ISAAC data showed that between
1995 and 2002 there was a considerable decrease
in the prevalence of flexural rash in the previous
12 months among 12–14-year-olds in Scotland
from 17% to 13%.12 No data on ethnicity were
reported for the Scottish ISAAC data.
The only deaths recorded for allergic disease
were for asthma. There were 100 asthma deaths
(ICD10 J45-J46) in Scotland in 2005, these occurring
at a rate of approximately 20 per million of the
population. There were no recorded deaths from
any other allergic problem.
Health service utilization
Primary care
There were 60,553 GP consultations for allergy in
2003–2004. The consultation rate for all allergies
was 39 (95% CI 39–39) per 1000 registered patients
in 2003–2004 (Table 2) which was nearly 4% of all
consultations for that year. The allergic conditions
for which patients most commonly consulted GPs
were asthma (20 [95% CI 20–20] consultations per
1000 registered patients annually, or nearly half
of all GP consultations for allergic disease) and
eczema (10 [95% CI 10–10] per 1000 registered
patients).
Over 7.7 million community prescriptions were
dispensed for allergic conditions in Scotland in
2003–2004, 13% of all prescriptions dispensed
for that year. These were mainly for eczema
(1.8 million) and asthma (1.7 million).
Secondary care
There were 24,189 admissions for all allergic dis-
orders in 2004–2005, accounting for 1.5% of the
total admissions for all conditions in that year.
Of these, asthma was the commonest reason and
accounted for 83% of allergic disease continuous
inpatient stays. In the financial year 2004–2005
there were 1455 continuous inpatient stays for
other allergic problems (urticaria=286; anaphy-
laxis=370; atopic dermatitis=245; food allergy=296;
allergic rhinitis=93; angioedema=156 and conjunc-
tivitis=9). The highest rates were for asthma in
children under 15 (35.5 per 1000, Table 3), followed
by eczema (1.83 per 1000) in the same age group.
Around 10% of hospital discharges included infor-
mation on ethnic group, insufficient to allow
meaningful analysis.
Healthcare costs
GP consultations for allergic problems in Scotland
cost the NHS an estimated £1.5 million per year,
hospital admissions £10.2 million per year and
community prescribed treatments for allergic con-
ditions nearly £120 million (Table 4). Overall,
allergic disease costs the NHS over £130 million
per year in direct costs. Asthma was the major
contributor across all cost domains (Table 4).
Primary care prescribing costs for all condi-
tions amounted to nearly £1 billion, of which pre-
scriptions for all allergic problems accounted for
13% (nearly £120 million) of this budget; this com-
pared to 11% for gastrointestinal problems (nearly
£104 million).
Table 2
GP consultation rates per 1000 GP consultations per year, (95%
confidence intervals, source, PCCIU) Scotland 2003–2004
Disease GP consultations per 100,000 per year
(95%CI)
All allergic conditions 39 (39–39)
Allergic rhinitis 4.3 (4.3–4.3)
Anaphylaxis 0.03 (0.03–0.003)
Angioedema 0.03 (0.03–0.03)
Asthma 20 (20–20)
Allergic asthma 0.34 (0.34–0.34)
Conjunctivitis 0.53 (0.53–0.53)
Drug allergy 0.72 (0.72–0.73)
Eczema 10 (10–10)
Food allergy 0.16 (0.16–0.17)
Urticaria 1.6 (1.6–1.6)
Other allergy 1.2 (1.2–1.2)
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Discussion
Main findings of this study
This is the most comprehensive and detailed re-
view of the disease burden posed by allergic disor-
ders in Scotland ever undertaken. We have found
that allergic disorders are extremely common, af-
fecting over one in three of the Scottish population
at some point in their lives. The majority of these
individuals are affected by one or more of the
organ-specific allergic disorders, namely eczema,
allergic rhinitis and/or asthma. Also, the lifetime
prevalence for all allergic disease was higher in
Scotland than England, namely for allergic rhinitis,
asthma and eczema, but not for anaphylaxis. This
analysis also reveals that these conditions are as-
sociated with significant costs to NHS Scotland
(over £130 million), which are predominantly as-
sociated with the provision of asthma care and
community-based prescribing.
Strengths and limitations of this work
The main strengths of this work include the use of
data from a number of large and representative
data-sets, the inclusion of a broad range of allergic
conditions enabling us to include possible diag-
nostic transfer (for example, between angioedema
and urticaria), and the use of a range of relevant
epidemiological, health services utilization and
cost-related outcomes. In addition, wewere able to
draw on our collective understanding and experi-
ence of working with these data-sets, and, more
specifically, data relating to allergic disorders, in
order to interpret findings.
This work does however have a number of
important potential limitations, these in the
main relating to the available data sources. These
include, most notably, the fact that wewere depen-
dent on recorded clinical diagnoses in both pri-
mary and secondary care, and also in relation to
coding of deaths. This latter issue is, for example,
known to be a potential problem in relation to the
underestimate of deaths from anaphylaxis, which
are often coded as asthmadeaths.24 In addition, the
discordant time periods of each data-set made
comparisons between data-sets slightly challeng-
ing. There are also potential problems in relation
to interpreting data on trends as these can be
affected by incentives to improve quality of care
(for example, the Quality and Outcomes Frame-
work),14 healthcare changes (for example, bed
availability, commissioning priorities and other
policy changes), changes in perceptions (for
example, greater public awareness of food allergy)
and data artefacts.
There are also limitations imposed by infor-
mation gaps, such as the lack of data on allergic
reactions in dentistry, utilization of out-of-hours
primary care (NHS24), accident and emergency
attendances, outpatient care, inpatient prescribing,
some over-the-counter purchases of drugs for
eczema and allergic rhinitis in particular, and in
many cases regional, socioeconomic and ethnic
variations in allergic disease risk and outcomes.As
a consequence of this, our estimates of costs to the
NHS are likely to be a substantial underestimate.
Table 3
Continuous inpatient stays for allergic conditions in Scotland (rate of admissions per year, per 1000
population) in 2004–2005
Disease Total Men Women 0–14 15–44 45+
All allergic disease 12 10 15 44 15 6
Allergic rhinitis 0.13 0.14 0.12 0.39 0.26 0.3
Anaphylaxis 0.52 0.45 0.60 0.74 0.74 0.39
Angioedema 0.22 0.18 0.27 0.13 0.25 0.22
Asthma 9.9 8.0 12.2 35.5 12.1 0.47
Conjunctivitis 0.01 0.02 0.00 0.07 0.01 0.00
Eczema 0.34 0.35 0.34 1.83 0.36 0.09
Food allergy 0.42 0.42 0.42 0.258 0.26 0.12
Urticaria 0.40 0.36 0.45 1.37 0.53 0.18
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Considering the findings of this work in
relation to the wider literature
Prospective cohort studies are needed to allow a
more accurate characterization of the epidemiol-
ogy of allergic disorders in Scotland. In the absence
of such studies, which are of necessity time-
consuming and expensive tomount, it is important
that secondary analysis of cohorts generated using
routine data-sets is undertaken25 and furthermore
that in-depth work is undertaken to assess the
validity of routine clinical records as has, for
example, been undertaken in relation to anaphy-
laxis records from the General Practice Research
Database (GPRD).26 Similar work is now needed
for hospital-based data-sets. Consideration also
needs to be given to including a much broader
range of allergy questions in the SHS.
Given the lack of data on ethnicity, it is impor-
tant to consider bridging this gap using the data
linkage techniques recently developed by Bhopal
et al.,27 which allow linkage of healthcare records
with census ethnicity codes using a probabilistic
matching technique. Similarly, to obtain a broader
picture of costs to society associated with allergic
disorders, it is important to consider, for example,
the impact on school andwork performance,28 and
this should also prove possible with greater invest-
ment in data-linkage techniques.9
The gaps in recoding of emergency contacts
within the NHS – NHS24 and A&E attendance –
also need to be filled and this may prove possible
in due course when the electronic health record is
introduced into NHS Scotland. Outpatient record-
ing by diagnosis has begun but is at an early stage.
Given the likely future move to the Systematised
Nomenclature of Medicine Clinical Terms
(SNOMED-CT) coding system, it is important that
serious consideration is given to ways in which
allergy codes need to be developed to facilitate
secondary analyses of the type undertaken in this
study.29
More specifically, given the relatively rapid
changing epidemiology of allergic disorders, it is
important to continue to monitor allergic disease
trends and use the variation discovered therein for
hypothesis generation and to provide the data
needed to inform assessments of the feasibility of
mounting much needed clinical studies of allergic
disease prevention and management.
Conclusions
Allergic diseases are extremely common in Scot-
land and are responsible for substantial morbidity,
healthcare utilization and costs to the NHS. Evi-
dence suggests that the previous increases in al-
lergic disorder prevalence reported throughout the
latter half of the 20th century may be stabilizing,
Table 4
GP consultations, 2003–2004 (source PCCIU), hospital inpatient
costs and community prescriptions 2004–2005 (source ISD) for
Scotland. Cost in £1000s
Primary/secondary care Cost (£1000s)
GP Allergic rhinitis 167
Anaphylaxis 1
Angioedema 1
Asthma 786
Conjunctivitis 20
Drug allergy 28
Eczema 397
Food allergy 6
Urticaria 61
Other allergy 47
All allergies 1514
Hospital,
admissions
Asthma
Inpatient 2391
Day case 122
All allergy excluding asthma Inpatient
Allergic rhinitis 454
Anaphylaxis 220
Angioedema 105
Conjunctivitis 6
Eczema 223
Food allergy 167
Urticaria 223
Other allergy 4496
All allergy excluding asthma Day case
Allergic rhinitis 175
Anaphylaxis 2
Angioedema 1
Conjunctivitis 1
Eczema 63
Food allergy 51
Urticaria 34
Other allergy 1486
Total hospital admissions 10,220
Community
prescriptions
Asthma 94,867
Adrenaline 733
Topical corticosteroids 6572
Emollients 5898
Antihistamines 11,887
Total community prescriptions 119,9577
Overall total 131,691
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but given the very high proportion of children now
affected, allergic conditions are likely to represent
a major strain on the NHS in Scotland for many
years to come. Although Scotland has some excel-
lent data-sets, these are in relation to allergic con-
ditions at present disparate, incomplete and
complex to analyse and interpret. Given these limi-
tations, consideration needs to be given to setting
up a long-termWorkingGroup to ensure that some
of the methodological limitations uncovered by
this study can be overcome and maximum use is
made from the opportunities associatedwith intro-
duction of SNOMED-CT and the electronic health
record.
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Appendix 1
Questions on allergy used in
survey data
Scottish Health Survey 1998 and 2003
1998 and 2003
+ Have you ever had wheezing or whistling in
the chest at any time, either now or in the past?
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+ Have you ever had this wheezing or whistling
when you did not have a cold?
+ Have you ever been at all breathless when the
wheezing or whistling noise was present?
+ Have you ever had wheezing or whistling in
the chest in the last 12 months?
+ How many attacks of wheezing/whistling
have you had in the last 12 months?
+ In the last 12 months, how often on average
has your sleep been disturbed due to
wheezing/whistling?
+ In the last 12 months, has the wheezing/
whistling ever been severe enough to limit
your speech to only one or two words at a time
between breaths?
+ In the last 12 months, how much did
wheezing/whistling interfere with your
normal daily activities?
+ When was your most recent attack of
wheezing/whistling?
+ Did a doctor ever tell you that you had
asthma? Exclude: homeopaths, etc.
+ When was your most recent attack of asthma?
+ Have you received any treatment or advice for
your (asthma/wheezing or whistling) from
any of the people on this card?
 Which ones? Any others?
 Ageneral practitioner (GP)
 Nurse at GP surgery/Health centre
 Community, School or District Nurse
 Hospital casualty/Accident and
Emergency department
 Consultant/Specialist or other doctor at
hospital outpatients
 Consultant/Specialist or other doctor
elsewhere
 Homeopath
 Acupuncturist
 Other alternative medicine professional
+ How many times were you treated by a
general practitioner for your (asthma/
wheezing or whistling) in the last 12 months?
+ How many times were you treated by a nurse
at a GP surgery/Health centre for your
(asthma/wheezing or whistling) in the last
12 months?
+ How many times were you treated by a
Community, School or District nurse for your
(asthma/wheezing or whistling) in the last
12 months?
+ How many times were you treated at a
hospital casualty or Accident and Emergency
Department for your (asthma/wheezing or
whistling) in the last 12 months?
+ How many times were you treated by a
Consultant/Specialist or other doctor at
hospital outpatients for your (asthma/
wheezing or whistling) in the last 12 months?
+ How many times were you treated by a
Consultant/Specialist or other doctor
elsewhere for your (asthma/wheezing or
whistling) in the last 12 months?
Health Survey for England 2001
+ Have you ever had wheeze or whistling in the
chest?
+ Have you ever had this wheezing or whistling
when you did not have a cold?
+ Have you ever been at all breathless when the
wheezing or whistling noise was present?
+ Have you had wheeze or whistling in the chest
in the last 12 months?
+ Have you been doctor-diagnosed with asthma?
International Survey of Asthma and Allergies
in Childhood (ISAAC), 1995 and 2002, for
12–14-year-olds
+ Have you had wheeze or whistling in the chest
in the last 12 months?
+ How many attacks of wheezing have you had
in the last 12 months?
+ In the last 12 months, how often, on average,
has your sleep been disturbed due to
wheezing?
+ In the last 12 months, has wheezing ever been
severe enough to limit our speech to only one
or two words at a time between breaths?
+ Have you ever had asthma?
+ In the past 12 months, have you had a problem
with sneezing, or runny or blocked nose when
you DID NOT have a cold? In the last
12 months, has this nose problem been
accompanied by itchy-watery eyes?
+ Have you ever had hayfever?
+ Have you ever had an itchy rash which was
coming and going for at least 6 months? Have
you had this itchy rash at any time in the last
12 months? Has this itchy rash affect any of
the following places: the folds of the elbows,
behind the knees, in front of the ankles,
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under the buttocks, or around the neck, ears or
eyes?
+ Have you ever had eczema?
Appendix 2
Data sources
Surveys
Scottish Health Survey
The Scottish Health Survey (SHS) consists of a
series of three national surveys of the Scottish
population conducted in 1995, 1998 and 2003. The
1995 survey included adults aged 16–64 years.
The 1998 survey was extended to include children
aged 2–15 years and the upper age limit increased
to 74 years. The 2003 survey included infants
aged under 2 years, with no upper age limit. The
questions from the SHS survey can be found in
Appendix 2.
Health Survey for England
The Health Survey for England (HSE) is part of a
wider programmeof surveys commissioned by the
Department of Health and is designed to monitor
trends in the nation’s health. The survey focuses on
different health issues each year. Only certain
years cover respiratory and allergic disease; 2001
and 2002 were the last published surveys to do so.
Data from the 2001 survey were used in this study
as these data were used to compare with SHS data
in the SHS report. The questions from the HSE
survey can be found in Appendix 2.
International Study of Asthma and Allergy in
Children
The International Study of Asthma and Allergy in
Children (ISAAC) study, conducted in 55
countries, sought to estimate the prevalence of
symptoms of asthma, hayfever and atopic derma-
titis (and associated diagnoses) in 6–7-year-olds
and 13–14-year-olds and to investigate for evi-
dence of geographical variations in disease preva-
lence. In the Scottish data, Scottish Islands are
included in Scottish results. Data are shown for
phase I and II surveys (10). Specific Scottish data
were not available for phase III (11). The questions
used in the ISAAC survey can be found in
Appendix 2.
Primary care data
PracticeTeam Information
Practice Team Information (PTI) collects data on
patients’ encounters with members of the practice
team, including general practitioners (GPs), and
practice and community nurses. Data for 2003–
2004 to 2005–2006 included 42–45 practices. The
programme is part of the Information Services
Division (ISD) of NHS National Services Scotland.
The system developed from Continuous Mor-
bidity Recording (CMR), which collected data
from contacts between GP and patient.
Quality and Outcomes Framework
Since 2004 the General Medical Services contract
with GPs has included incentive payments for
achieving a set of quality indicators through the
Quality and Outcomes Framework (QOF) (12).
These include quality indicators for asthma care.
Data from the asthma register used for assessing
quality outcomes can be used as a measure of
prevalence. The number of people on asthma reg-
isters is influenced by the quality and complete-
ness of GP recording. The registers exclude people
who have not been prescribed asthma-related
drugs in the preceding 12 months and those on the
chronic obstructive pulmonary disease (COPD)
register.
Primary Care Clinical Informatics Unit
In April 2000, the Primary Care Clinical Informat-
ics Unit (PCCIU) was created as part of a national
primary care initiative. It provides the informatics
support for the Scottish Programme for Improving
Clinical Effectiveness (SPICE), part of the Clini-
cal Effectiveness Programme developed by the
Royal College of General Practitioners (Scotland).
PCCIU’s aim is to help GPs understand their clini-
cal information needs through a variety of feed-
back reports based on data extraction from their
practice. As part of the SPICE programme (techni-
cally managed by PCCIU), data entry templates
were developed for use by clinicians to sys-
tematically record data about a number of chronic
conditions. From 2003 onwards, these templates
were modified to include all information required
for the new contract. Diagnostic criteria are not
specified. Instead, clinical diagnoses are those re-
corded through routine practice, which, for major
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conditions, is often after investigation and input
from hospital-based specialist colleagues.
Anonymized retrospective data from all 310 of
the 850 Scottish practices who use the General
Practice Administrative Software System (GPASS)
and also participate in SPICE were obtained in
November 2005. The completeness and accuracy
of morbidity and repeat prescribing data in GPASS
practices have been reported previously. A subset
of 58 SPICE practices, representative of the Scottish
population and routinely collecting morbidity
data as part of the PTI project in 2004, were used
for these analyses. The allergy Read codes used to
extract PCCIU data can be found in Appendix 3.
QRESEARCH
The Scottish PCCIU data were compared to data
from the QRESEARCH database. This database is
one of the largest anonymized aggregated health
databases in the world and contains the records of
over nine million patients from 525 UK general
practices in England (further information can be
found at www.qresearch.org).
Prescribing and medication
Prescription Cost Analysis
ISD obtains information from prescriptions dis-
pensed in the community by pharmacists, dispens-
ing doctors and appliance suppliers. Prescription
Cost Analysis (PCA) shows details of the number
of items and the Gross Ingredient Cost (GIC) of
all prescriptions dispensed in the community in
Scotland.
Over-the-counter sales
The data from Intercontinental Marketing Services
(IMS) include the sales for allergic rhinitis, asthma
and eczema products in Scotland. These data
are taken from retail pharmacies, but do not
include data for Boots and Superdrug; they also do
not include data on sales classified as ‘groceries’.
For further details see http://www.imshealth.com
/ims/portal/pages/homeFlash/europe/0,2768,
6025,00.html.
Hospital admissions
Scottish Morbidity Record
ISD collects information on inpatient and day-case
episodes in Scottish hospitals through the Scottish
Morbidity Record (SMR01) scheme. Information
includes a principal diagnosis and up to five
additional diagnoses for each hospital episode.
Patient episodes are linked into continuous hospi-
tal stays and also with information on deaths pro-
vided by the General Register Office for Scotland
(GROS). Inpatient diagnoses are classified using
the International Classification of Diseases (ICD);
ICD-9 was used up to 1996 and ICD-10 thereafter.
The allergy ICD codes used to extract ISD data can
be found in Appendix 3.
Mortality
General Register Office for Scotland:
Registered deaths
The GROS produces information on deaths and on
population estimates that can be used to calculate
population-based rates. Deaths are coded using
the ICD-9 classification up to 2000 and ICD-10
thereafter. Further details are available at http://
www.gro-scotland.gov.uk/.
Appendix 3 Read codes for
allergic conditions
Clinical term Read codes (1)
1. Allergic rhinitis
allergic rhinitis H17. and all codes
below heading
Vasomotor rhinitis H18.
Other seasonal allergic
rhinitis
Hyu20
Other allergic rhinitis Hyu21
Other chronic sinusitis Hyu22
2. Anaphylaxis
Anaphylaxis SN50. and all codes
below heading
SP34. (due to serum)
Anaphylactic shock SN50. and all codes
below heading
3. Angioneurotic
oedema
Angioneurotic oedema SN51
4. Asthma
All asthma (for
comparison only)
H33. and all codes
below heading
173A. (exercise-induced
asthma)
Allergic asthma
Allergic asthma H330. and all codes
below heading
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Clinical term Read codes (1)
1780. (aspirin-induced
asthma)
H47y0
(detergent-induced
asthma)
Wheezing R0609 ([D] wheezing)
1737 (wheezing)
5. Conjunctivitis
Allergic conjunctivitis F4C14 (chronic)
F4C06 (acute atopic)
F4C14 (other chronic
allergic conjunctivitis)
6. Drug allergy
drug allergy SN52. and all codes
below heading
7. Eczema/ dermatitis
allergic (intrinsic)
eczema
M114
M11z. (atopic dermatitis
NOS)
Allergic dermatitis and
related
M11.
Atopic
dermatitis/eczema
M111
Infantile eczema M112
Flexural eczema M113
Contact or allergic
eyelid dermatitis
F4D31
Neurodermatitis –
atopic
M117
Allergic contact
dermatitis
M128. and all codes
below heading
Dermatitis NOS M12z0
Eczema NOS M12z1
Infected eczema M12z2
Hand eczema M12z3
Erythrodermic eczema M12z4
8. Food allergy
Food allergy SN58. and all codes
below heading
History of food allergy 14M1
9. Urticaria
Urticaria M28. and all codes
below heading
10. Other allergy
Allergic parotitis J0720
Allergic gastritis J1540
Allergic gastroentiritis
and colitis
J432. and all codes
below heading
Coeliac disease J690. and all codes
below heading
Chronic allergic otitis
media
F5130
Clinical term Read codes (1)
Allergic otitis media
NOS
F5140
Allergy SN53. and all codes
below heading
Venom allergy SN59. and all codes
below heading
Allergic arthritis N062. and all codes
below heading
Skin: type 3 delayed
reaction
3354
Skin: type 1 immediate
reaction
3355
Skin: type 4 late
reaction
3356
Allergy skin test
positive
3359
Allergy test positive 3368
Allergic purpura D310. and all codes
below heading
Allergic eosinophilia D4033
Appendix 4 ICD codes for allergic
conditions
Condition ICD-9 Codes ICD-10 Codes
Allergic rhinitis 477 Allergic
rhinitis
J30.1 Allergic
rhinitis due to
pollen
J30.2 Other
seasonal
allergic rhinitis
J30.3 Other
allergic rhinitis
J30.4 allergic
rhinitis,
unspecified
Anaphylaxis 995.0
Anaphylactic
shock
T78.0
Anaphylactic
shock due to
adverse food
reaction
999.4
Anaphylactic
shock due to
serum
T78.2
Anaphylactic
shock,
unspecified
T80.5
Anaphylaxis
due to serum
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Condition ICD-9 Codes ICD-10 Codes
T88.6
Anaphylactic
shock due to
adverse effect
of correctly
administered
medication
Asthma 493 Asthma J45 Asthma
J46 Status
asthmaticus
Conjunctivitis 372.1 Chronic
conjunctivitis
H10.1 acute
atopic
conjunctivitis
372.3 Other and
unspecified
conjunctivitis
Eczema/
Dermatitis
691 Atopic
dermatitis and
related
conditions
L20 Atopic
dermatitis
692 Contact
dermatitis and
other eczema
L23 Allergic
contact
dermatitis
Condition ICD-9 Codes ICD-10 Codes
Food allergy 693.1
Dermatitis due
to food
L27.2
Dermatitis due
to food
T78.1 Other
adverse
reactions to
food
Urticaria /
Angioedema
708 Urticaria L50 Urticaria
995.1
Angioedema
T78.3
Angioedema
Other allergy 995.3 Allergy
unspecified not
elsewhere
classified
T78.4 Allergy,
unspecified
T63.4 Toxic
effect due to
venom of
other
arthropods
989.5 Toxic
effect of venom
Appendix 5
Age–sex standardized lifetime prevalence per 1000 (95% CI) patients in Scotland (2004, PCCIU) and
England (2005, QRESEARCH). Both sets of data are standardized to English population (2004)
Country All allergic disease Allergic rhinitis Anaphylaxis Asthma Eczema
Scotland 350 (348–352) 89 (88–90) 0.67 (0.58–0.75) 121 (120–122) 161 (160–162)
England 243 (243–245) 66 (66–67) 0.72 (0.72–0.79) 113 (113–113) 115 (115–116)
Appendix 6
Prevalence (%) of wheeze and doctor-diagnosed asthma for men and women (aged 16 years and over)
and children (15 years and under), Scotland 2003 (source Scottish Health Survey).
Lifetime wheeze (%) Wheezed in last 12
months (%)
Doctor diagnosed
asthma ever (%)
Men 27 16 13
Women 26 16 14
Boys 29 16 20
Girls 20 12 12
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